Daniel R. Chevallard, the chief financial officer of LENZ Therapeutics, Inc. (NASDAQ: LENZ), reported a personal acquisition of company shares on March 27, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The filing shows Chevallard purchased 7,500 shares of LENZ common stock at $8.57 per share, for a total outlay of $64,275. After completing this transaction, Chevallard directly holds 12,886 shares of the company's stock.
This insider purchase came as LENZ stock was trading near its 52-week low of $8.39, following a 24% decline over the prior week. Analysis noted on InvestingPro describes the stock as appearing undervalued at current levels and reports technical indicators that point to an oversold condition. InvestingPro’s coverage also highlights LENZ’s balance-sheet metrics, noting the company has more cash than debt and records a current ratio of 14.23. Investors interested in additional detail are directed to LENZ’s Pro Research Report, which is available on InvestingPro along with coverage of more than 1,400 other U.S. equities.
LENZ’s recent quarterly filing covering Q4 2025 disclosed that the company entered the revenue column for its presbyopia treatment, VIZZ, delivering initial commercial receipts. The company reported a robust cash position at quarter end, but the quarter also included higher operating expenses that resulted in a substantial quarterly net loss.
Commercial efforts for VIZZ formally began in October 2025, and broad availability of the product was achieved by mid-fourth quarter 2025. Given that timeline, LENZ’s reported revenue for that quarter reflects less than one full quarter of product adoption.
In connection with these developments, H.C. Wainwright maintained a Buy rating on LENZ and kept a $56.00 price target, citing year-end trends that showed early adoption patterns for VIZZ.
Key points:
- LENZ CFO Daniel R. Chevallard bought 7,500 shares on March 27, 2026, at $8.57 per share, totaling $64,275 and bringing his direct holdings to 12,886 shares.
- The stock traded near a 52-week low of $8.39 after a 24% decline over the prior week; InvestingPro labels the shares undervalued with oversold technicals and highlights a strong liquidity position with a current ratio of 14.23.
- LENZ recorded initial revenue from VIZZ in Q4 2025 amid a strong cash position but also reported higher operating expenses and a substantial quarterly net loss; VIZZ commercialization began in October 2025 with broad availability by mid-Q4.
Risks and uncertainties:
- Market volatility - the stock’s recent 24% weekly decline and trading near its 52-week low indicate market-side risk affecting equity investors in LENZ and the broader biotech sector.
- Profitability pressure - increased operating expenses contributed to a substantial quarterly net loss, presenting execution and cost-management risk for the company and impacting investor returns.
- Limited adoption period - revenue from VIZZ reflects less than one full quarter of commercial availability, leaving uncertainty about the pace and scale of future product uptake.
These items outline the immediate financial and market backdrop for LENZ Therapeutics following the disclosed insider purchase and the company’s initial commercial results for VIZZ.